NY-FINSBURY-GLOVER-HERNG
7.7.2020 12:02:08 CEST | Business Wire | Press release
Finsbury, The Glover Park Group (GPG) and Hering Schuppener are joining together to create the preeminent global strategic communications and public affairs consultancy. The new firm, Finsbury Glover Hering, will combine the complementary strengths of three of the world’s most respected advisory firms to counsel chief executives, boards and leaders at public and private companies, leading institutions and nonprofit organizations. The combination formalizes the strategic partnership between the three WPP companies, which was formed by Finsbury and Hering Schuppener in 2016 and which GPG joined in 2017.
At a time when companies and institutions face heightened expectations of purpose and transparency, as well as increased public and stakeholder scrutiny, Finsbury Glover Hering is uniquely equipped to provide integrated, tailored solutions to help organizations navigate the financial, legal, regulatory, societal and stakeholder complexities they must consider in shaping their communications. Clients will benefit from Finsbury Glover Hering’s global network of nearly 700 experts in 18 offices in the world’s major financial, government, business and cultural centers, where the firm builds on strong local foundations forged through decades of experience.
The new firm will lead the industry in:
- Public affairs and issues management, with deep policy expertise, a reputation for results and unmatched networks in the world’s capitals;
- Capital markets communications, having advised on more than 1,500 transactions with a total value of more than $2 trillion over the past decade alone; and
- Corporate, crisis and transformation communications, successfully positioning CEOs and other leaders, steering major public and private companies through high-stakes moments of change and helping launch or re-launch organizations to industry leader status.
Finsbury Glover Hering will launch in early 2021. Finsbury founder Roland Rudd and GPG founder Carter Eskew will co-chair the new firm. Alexander Geiser, Managing Partner at Hering Schuppener, will serve as Chief Executive Officer with the support of seasoned global and regional management teams.
Finsbury Glover Hering will be driven by the highly entrepreneurial spirit that inspired its founder firms and intends to offer equity to recruit, retain and incentivize the best established and emerging talent in communications and public affairs. The management team will be investing in the new firm and will own 49.99% of the company alongside WPP, which will retain a majority interest. Mark Read, the CEO of WPP, will also join the Board of Directors of the newly integrated company.
Mark Read said: “We see in Finsbury Glover Hering a tremendous opportunity to establish a new global powerhouse in the strategic communications industry alongside a very talented and highly respected group of leaders. It also aligns with WPP’s strategy of creating simpler, stronger and more integrated client offers.”
Roland Rudd, co-Chairman and founder of Finsbury, commented: “Each of our firms is best in class and together create a new global standard for strategic advice and communications - we’d like to thank our clients for the trust they have placed in us as individual firms over the last decades.”
“We founded GPG with a highly entrepreneurial spirit, and we’re thrilled that we can now also offer a more sustainable value proposition to future generations,” said co-Chairman Carter Eskew.
CEO Alexander Geiser said: “With one global brand, balance sheet and governance, we are formally implementing what has long been reality for us. One firm, one team.”
The company will be headquartered in New York City, with operations in Abu Dhabi, Beijing, Berlin, Brussels, Dubai, Dublin, Düsseldorf, Frankfurt, Hong Kong, London, Los Angeles, Moscow, Riyadh, Shanghai, Singapore, Tokyo and Washington, D.C.
About Finsbury Glover Hering
Finsbury Glover Hering is a new preeminent global strategic communications advisory firm, headquartered in New York City, with almost 700 multidisciplinary experts across the world’s major financial, government, business and cultural centers. The company was formed through the merger of the leading strategic communications consultancies Finsbury, The Glover Park Group (GPG) and Hering Schuppener. The firm provides combined support in Government Relations & Policy and Advocacy, Corporate Reputation & Leadership Strategies, Crisis & Issues Management, Transaction & Financial Communications as well as Business Transformation, supported by Research and Insights, Digital Strategy, Media Planning and Creative Solutions.
Finsbury Glover Hering serves its global client base from offices in Abu Dhabi, Beijing, Berlin, Brussels, Dubai, Dublin, Düsseldorf, Frankfurt, Hong Kong, London, Los Angeles, Moscow, New York, Riyadh, Shanghai, Singapore, Tokyo and Washington, D.C.
Find more information visit www.fgh.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200707005391/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
